Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
June 18 2020 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that Company management,
including Mike Sherman, Chief Executive Officer, and Mike Andriole,
Chief Business and Financial Officer, will participate in a
fireside chat at the H.C. Wainwright Virtual Fireside Chat Series
on Thursday, June 25, 2020 at 12:05 p.m. ET.
A live audio webcast of the chat will be available on the
Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
Dociparstat sodium is a potential first-in-class
glycosaminoglycan compound derived from porcine heparin that may be
dosed at much higher levels without triggering bleeding
complications. In vitro and in vivo animal model data support
DSTAT’s potential to reduce the inflammation and cellular
infiltration associated with acute lung injury and address
coagulation disorders associated with COVID-19 pathology (HMGB1 and
PF4). Separately, DSTAT inhibits the activities of several key
proteins implicated in the viability of AML blasts and leukemic
stem cells in the bone marrow during chemotherapy (e.g., CXCL12,
selectins, HMGB1, elastase). Randomized AML Phase 2
data suggest that DSTAT may also accelerate platelet recovery
post-chemotherapy via inhibition of PF4, a negative regulator of
platelet production that impairs platelet recovery following
chemotherapy. The company is conducting a randomized,
double-blind, placebo-controlled, Phase 2/3 trial to determine the
safety and efficacy of DSTAT in adults with severe COVID-19 who are
at high risk of respiratory failure. The Phase 2 portion of the
study will enroll 24 subjects to confirm the maximum safe dose and
will then expand by an additional 50 patients (74 total) at the
selected dose. A formal analysis of all endpoints, including
supportive biomarkers will be performed at the conclusion of the
Phase 2 portion of the study. Contingent upon positive results, the
Phase 3 portion of the study will enroll approximately 450
subjects.
BCV is an antiviral drug candidate in development as a medical
countermeasure for smallpox. For further information, please visit
the Chimerix website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things, the
mechanism of action of DSTAT and its potential in ALI patients with
COVID-19; Chimerix’s ability to develop DSTAT, including the
initiation of a Phase 2/3 clinical trial for DSTAT as a potential
treatment for ALI associated with COVID-19; Chimerix’s ability to
submit and/or obtain regulatory approvals for DSTAT and BCV; and
the timing and receipt of a potential procurement contract for BCV
in smallpox. Among the factors and risks that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks that DSTAT may not achieve the
endpoints of the Phase 2/3 clinical trial; risks that DSTAT may not
obtain regulatory approval from the FDA or such approval may be
delayed or conditioned; risks that development activities related
to DSTAT may not be completed on time or at all; Chimerix’s
reliance on a sole source third-party manufacturer for drug supply;
risks that ongoing or future trials may not be successful or
replicate previous trial results, or may not be predictive of
real-world results or of results in subsequent trials; risks and
uncertainties relating to competitive products and technological
changes that may limit demand for our drugs; risks that our drugs
may be precluded from commercialization by the proprietary rights
of third parties; and additional risks set forth in the Company's
filings with the Securities and Exchange Commission. These
forward-looking statements represent the Company's judgment as of
the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
CONTACT:Investor
Relations:
Michelle LaSpaluto 919 972-7115 ir@chimerix.com Will O’Connor Stern
Investor Relations will@sternir.com 212-362-1200
Media ContactDavid SchullRusso
Partners858-717-2310David.Schull@russopartnersllc.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024